Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer

Xi Wang, Jing Ni, Chen Long Hsu, Sharlin Johnykutty, Ping Tang, Yuan Soon Ho, Chia Hwa Lee, Shuyuang Yeh

研究成果: 雜誌貢獻文章同行評審

18 引文 斯高帕斯(Scopus)

摘要

We show that TAP/Sec14L2 had a high expression in normal/benign breast, prostate, and liver tissues as compared to lung, colon, and kidney. Its expression was downregulated in breast cancer cell lines shown by quantitative-PCR. Further, 57% of 141 human invasive breast carcinomas had no or markedly reduced TAP/Sec14L2 expression by immunohistochemical staining, and the rate increased to 80% in high grade invasive carcinomas ( p <.01). This downregulation of TAP/Sec14L2 was also present in ductal carcinoma in situ(DCIS) associated with invasive carcinomas. These findings raise the possibility that TAP/Sec14L2 may serve as a tumor suppressor in breast carcinogenesis.
原文英語
頁(從 - 到)971-977
頁數7
期刊Cancer Investigation
27
發行號10
DOIs
出版狀態已發佈 - 十一月 13 2009

ASJC Scopus subject areas

  • 癌症研究
  • 腫瘤科

指紋

深入研究「Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer」主題。共同形成了獨特的指紋。

引用此